Bank of America Lowers Eli Lilly and (LLY) Price Target to $86.00

Eli Lilly and (NYSE:LLY) had its target price reduced by analysts at Bank of America from $88.00 to $86.00 in a report released on Thursday. The brokerage presently has a “neutral” rating on the stock. Bank of America’s target price indicates a potential upside of 4.13% from the company’s current price.

Several other equities research analysts also recently commented on the company. BMO Capital Markets upped their target price on Eli Lilly and from $73.00 to $74.00 and gave the company an “underperform” rating in a report on Thursday. Credit Suisse Group downgraded Eli Lilly and from a “neutral” rating to an “underperform” rating and set a $82.00 target price for the company. in a report on Monday, January 22nd. Jefferies Group set a $100.00 target price on Eli Lilly and and gave the company a “buy” rating in a report on Tuesday, January 16th. Goldman Sachs Group downgraded Eli Lilly and from a “buy” rating to a “neutral” rating and upped their target price for the company from $86.98 to $95.00 in a report on Tuesday, January 16th. Finally, Argus raised Eli Lilly and from a “hold” rating to a “buy” rating and upped their target price for the company from $85.52 to $115.00 in a report on Friday, January 5th. Four analysts have rated the stock with a sell rating, seven have given a hold rating and nine have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $92.13.

Shares of Eli Lilly and (LLY) traded up $1.14 during trading on Thursday, hitting $82.59. The stock had a trading volume of 4,485,934 shares, compared to its average volume of 4,505,981. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.03 and a current ratio of 1.38. The firm has a market capitalization of $94,793.27, a price-to-earnings ratio of 39.17, a price-to-earnings-growth ratio of 1.67 and a beta of 0.35. Eli Lilly and has a twelve month low of $76.55 and a twelve month high of $89.09.

Eli Lilly and (NYSE:LLY) last announced its quarterly earnings data on Wednesday, January 31st. The company reported $1.14 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.07 by $0.07. The business had revenue of $6.16 billion during the quarter, compared to analyst estimates of $5.93 billion. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The company’s revenue was up 7.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.95 earnings per share. equities research analysts expect that Eli Lilly and will post 4.22 EPS for the current year.

In related news, SVP Susan Mahony sold 36,585 shares of the company’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $86.18, for a total transaction of $3,152,895.30. Following the transaction, the senior vice president now directly owns 54,885 shares of the company’s stock, valued at $4,729,989.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Lilly Endowment Inc sold 200,000 shares of the company’s stock in a transaction on Wednesday, December 13th. The shares were sold at an average price of $88.20, for a total value of $17,640,000.00. Following the transaction, the insider now directly owns 123,084,104 shares in the company, valued at $10,856,017,972.80. The disclosure for this sale can be found here. Insiders have sold 251,088 shares of company stock worth $22,041,236 over the last three months. 0.20% of the stock is owned by insiders.

A number of hedge funds have recently modified their holdings of LLY. Acrospire Investment Management LLC increased its position in Eli Lilly and by 16.7% in the 2nd quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock worth $115,000 after purchasing an additional 200 shares during the last quarter. MPS Loria Financial Planners LLC acquired a new position in Eli Lilly and in the 2nd quarter worth about $128,000. San Francisco Sentry Investment Group CA acquired a new position in Eli Lilly and in the 2nd quarter worth about $129,000. Front Row Advisors LLC acquired a new position in Eli Lilly and in the 4th quarter worth about $137,000. Finally, Willingdon Wealth Management acquired a new position in Eli Lilly and in the 3rd quarter worth about $138,000. 76.53% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This report was posted by American Banking and Market News and is the sole property of of American Banking and Market News. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2018/02/01/bank-of-america-lowers-eli-lilly-and-lly-price-target-to-86-00.html.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Analyst Recommendations for Eli Lilly and (NYSE:LLY)